According to the World Health Organization, approximately 50 million people have epilepsy globally. It is one of the most common neurological diseases. As per data suggested by the Centers for Disease Control and Prevention, in the United States, 3 million people suffer from epilepsy. There has been a significant emphasis on developing effective seizure therapeutic products for neurological disorders as major companies and institutions are working towards innovative treatments for seizures.
Major companies involved in the seizure treatment market include GlaxoSmithKline, Jazz Pharmaceuticals, AstraZeneca, and Abbott among others.
Leading drugs currently under pipeline include XEN1101, and ZX008 among others.
Regulatory authorities such as the United States FDA and EMA play an essential role in the seizures pipeline landscape as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients suffering from seizures.
The Seizures Drug Pipeline Report by Expert Market Research gives comprehensive insights into seizures drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for seizures. The seizures report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from seizures.
The detailed seizures analytical perspective of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to seizures are covered.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A seizure is a sudden and uncontrolled burst of electrical activity in the brain, which can cause changes in movements, behavior, and levels of consciousness. It can occur after a head injury or a stroke and be caused by an infection such as meningitis. There are multiple types of seizures. The type of seizure varies from where they begin in the brain. The frequency of most seizures lasts from 30 seconds to two minutes. The symptoms of seizure include temporary confusion, staring spells, jerking movements of the legs and arms, loss of consciousness or awareness, and cognitive changes.
Seizures treatment includes the use of anti-seizure medicines. Different options for anti-seizure medicine are available in the market. Companies are developing innovative treatments to manage seizures. For instance, a phase III clinical trial study is being conducted to assess the effects of ZX008 when used as adjunctive therapy for the treatment of seizures. Several seizure therapeutic products in the pipeline are being developed by major pharma companies which has impacted the pipeline analysis for seizures.
This section of the seizures report covers the analysis of seizure drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s seizures clinical assessment of products covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s seizures clinical assessment covers 50+ drug analyses based on the route of administration.
The seizures pipeline insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with approximately 300 trials are currently in phase III.
The drug class categories covered under seizure pipeline analysis include sodium channel blockers, calcium channel blockers, gamma-aminobutyric acid (GABA), enhancers glutamate receptor antagonists. Sodium channel blockers inhibit voltage-gated sodium channels help in reducing neuronal excitability and prevent the spread of seizure. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for seizures.
The EMR report for the seizures pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in seizures clinical trials:
Cannabidiol oral solution is currently under phase II and is sponsored by INSYS Therapeutics Inc. The study is being conducted to assess the safety and tolerability of three multiple ascending doses of cannabidiol oral solution in patients.
A phase III study, sponsored by SK Life Science, Inc. is evaluating the safety and effectiveness of the drug to manage partial epilepsy in patients who have poor seizure control.
GlaxoSmithKline is developing the drug and it is currently under phase III. The study is investigating the safety and efficacy of seizures treatment retigabine dosed at 900 mg/day and 600 mg/day in epilepsy patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Seizures Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for seizures. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into seizures collaborations, market trends, regulatory environments, and potential growth opportunities within seizure drug pipeline insights.
Global Tonic-Clonic Seizures Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share